Effective immediately, Harvard Pilgrim has moved our preferred growth hormone products, Omnitrope and Tev-Tropin, from Tier 2 (Tier 3 on a 4-Tier formulary) to Tier 1 (Tier 2 on a 4-tier formulary) for members in our commercial plans. As a result, members who use these medications will be subject to a lower copayment.
Harvard Pilgrim requires prior authorization for all growth hormone products, and this will continue to apply to Omnitrope and Tev-Tropin. Omnitrope and Tev-Tropin do not require step therapy, while all other growth hormone products do.
Since growth hormone products are considered interchangeable, in early April, Harvard Pilgrim will notify members who use a non-preferred product that Omnitrope is now available for a lower copay. Because there is currently a shortage of Tev-Tropin, our member outreach will not encourage use of this medication.
In addition, one of Harvard Pilgrim’s specialty pharmacy vendors, Accredo, will contact prescribers of non-preferred growth hormone products to inform them that their patients can reduce their copay by switching to Omnitrope. In light of the Tev-Tropin shortage, Accredo will also contact prescribers of Tev-Tropin to notify them that any patients can switch to Omnitrope if they are having trouble obtaining Tev-Tropin.
To obtain prior authorization for growth hormone products, please complete the appropriate Medication Request Form and fax back to MedImpact Healthcare Systems at 888-807-6643.